Delivery Order SPE2DB24D2100-SPE2DB25FBFZA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,204.42 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector units on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy medication delivered via auto-injector,...
- The Defense Logistics Agency awarded a delivery order valued at $3,816.88 to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injector supplies. This non-set-aside, firm fixed-price delivery order was executed on August 12, 2025, with an ultimate completion date of August 13, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy product used in the treatment of hormone deficiency, representing part of the...
- The Defense Logistics Agency awarded a $1,270.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery...
- The Defense Logistics Agency awarded a $2,205.54 delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injectors on August 13, 2025, with completion targeted for August 14, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injection, representing part of the...
- The Defense Logistics Agency awarded a delivery order valued at $1,293.84 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same municipality....
- The Defense Logistics Agency awarded a delivery order valued at $2,393.02 to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy medication delivered via auto-injector,...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, with an ultimate completion date of July 21, 2025. This non-set-aside competitively awarded contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector medication valued at $1,127.92. This is a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFZADelivery Order
The Defense Logistics Agency awarded a $3,347.67 firm fixed price delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector units. The contract, issued on August 22, 2025, with completion targeted for August 25, 2025, represents a non-set-aside, competitively awarded procurement. Performance will be executed from the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive pharmaceutical supply vehicle supporting military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, leverages its prime IDC with DLA to supply a broad spectrum of pharmaceutical products and medical commodities to support military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates capability across multiple therapeutic domains and product categories through competitively awarded delivery orders featuring firm fixed pricing structures. This specific delivery order for testosterone replacement therapy auto-injectors supports the Defense Health Agency and other federal healthcare customers' pharmaceutical supply requirements under the broader DLA Troop Support Medical program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/22/25 |